The MeCo Score™ is the only clinically validated prognostic and predictive biomarker to identify patients with early-stage breast cancer who may benefit from antifibrotic therapy (1-4).
In effect, our technology has unlocked an entirely new class of therapies for breast cancer.
To maximize its forward compatibility as a companion diagnostic for emergent antifibrotic therapies, the MeCo Score™ is drug-agnostic, pathway-agnostic, and even mechanism-of-action-agnostic. It also demonstrates broad potential for other types of cancer.
As a clinical proof-of-concept, our landmark Phase 2 clinical study demonstrated that patients with High MeCo Score breast tumors who received antifibrotic therapy experienced a remarkable benefit: 62% reduced risk of recurrence over 9.7 years on average (p=0.031) (2,4).
This represents a stunning improvement in the long-term survival rate for a major subgroup of breast cancer patients.
Remarkably, the magnitude + duration of benefit appears to be unprecedented compared to all previous trials of targeted therapies that have ever been evaluated for early-stage breast cancer (4,5).
Partnerships & Collaborations
Funding
Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. doi: 10.1016/j.celrep.2021.109293
[2] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
[3] Mouneimne, G. et al. (2025). Cancers. doi: 10.3390/cancers17101632
[4] Event-free survival (EFS) after antifibrotic therapy (nintedanib) + chemotherapy vs. chemotherapy alone.
[5] Compared to randomized controlled trials that employed a chemotherapy or endocrine therapy backbone and demonstrated statistically significant results.
Note: The prescribing information for the FDA-approved therapy listed in the MeCo Score test report may not include the associated biomarker; the proposed intended use for the MeCo Score test and its cut-off value are subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the US Food and Drug Administration.
Copyright © 2025 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.